Kancera AB (Nasdaq First North Growth Market: KAN) reports results from an in-depth immunological analysis of blood samples from healthy subjects in the ongoing Phase Ib program. The analysis shows that KAND567 effectively blocks certain specific immune cells that are known to...
Read MoreThis is a translation of a press release in Swedish published in Stockholm 2019-11-22 Kancera AB (Nasdaq First North Growth Market: KAN) and Grünenthal work together to develop HDAC inhibitors for the treatment of pain and inflammation. The companies have now decided...
Read MoreThis is a translation of a press release in Swedish published 2019-11-21 Kancera AB (Nasdaq First North Growth Market: KAN) today announces that the company intends to complete the final phase of the Phase Ib study of the drug candidate KAND567 in...
Read MoreKancera AB (Nasdaq First North: KAN) announces the first public presentation of data for KAND567, its fractalkine receptor antagonist, in preclinical models of cardiovascular disease and its predicted translation to humans at the European Society of Cardiology (ESC) Congress 2019 in Paris,...
Read MoreKancera today announces that a further developed dosing strategy is intended to be tested for the treatment with KAND567. The reason is that the modified intravenous dosing studied in the phase Ib study in August 2019 resulted in a clearly improved but...
Read MoreKancera AB (Nasdaq First North: KAN) announces that the company's clinical Phase Ib study according to plan will start again today. The aim is to report the study in November 2019. Kancera also announces new financing through a third new issue of...
Read MoreKancera today announces that the third installment for the Fractalkine project and KAND567 is carried out according to the acquisition agreement. The payment that was activated in connection with the ongoing Phase Ib study takes place through a new issue of two...
Read MoreKancera AB (Nasdaq First North: CAN) today announced that two patent applications within the fractalkine project are now entering international phase and that the agreement with US Global Corporate Finance (GCF) has been utilized for a second new issue of 5,000,000 shares.
Read MoreKancera today announces positive interim results in the ongoing Phase Ib study of KAND567, which aims to study intravenous infusion of the drug candidate to healthy subjects. The first exploratory part of the study shows a good safety profile at shorter time...
Read MoreThe clinical Phase Ib study of intravenous administered KAND567 has started and is planned to be completed during the third quarter of 2019. KAND567 has previously been shown to be well tolerated and to have good pharmacokinetic properties when administered orally to...
Read More